Xeris Biopharma Holdings, Inc. (XERS)
16.97
+0.35
(+2.11%)
USD |
NASDAQ |
Nov 20, 16:00
17.01
+0.04
(+0.24%)
After-Hours: 20:00
Xeris Biopharma Holdings Research and Development Expense (TTM) : 38.38M for Sept. 30, 2026
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| September 30, 2026 | 38.38M |
| June 30, 2026 | 34.81M |
| March 31, 2026 | 32.20M |
| December 31, 2025 | 31.16M |
| September 30, 2025 | 29.38M |
| June 30, 2025 | 27.79M |
| March 31, 2025 | 25.49M |
| December 31, 2024 | 25.56M |
| September 30, 2024 | 25.85M |
| June 30, 2024 | 25.00M |
| March 31, 2024 | 25.32M |
| December 31, 2023 | 22.34M |
| September 30, 2023 | 20.91M |
| June 30, 2023 | 21.92M |
| March 31, 2023 | 19.55M |
| December 31, 2022 | 20.97M |
| September 30, 2022 | 26.29M |
| June 30, 2022 | 25.91M |
| Date | Value |
|---|---|
| March 31, 2022 | 27.38M |
| December 31, 2021 | 25.06M |
| September 30, 2021 | 19.29M |
| June 30, 2021 | 17.10M |
| March 31, 2021 | 17.21M |
| December 31, 2020 | 19.92M |
| September 30, 2020 | 27.83M |
| June 30, 2020 | 39.87M |
| March 31, 2020 | 53.92M |
| December 31, 2019 | 60.44M |
| September 30, 2019 | 60.41M |
| June 30, 2019 | 55.76M |
| March 31, 2019 | 45.11M |
| December 31, 2018 | 40.65M |
| September 30, 2018 | 34.84M |
| June 30, 2018 | 29.69M |
| March 31, 2018 | 25.22M |
| December 31, 2017 | 20.17M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| Ligand Pharmaceuticals, Inc. | 23.09M |
| MBX Biosciences, Inc. | 101.27M |
| ANI Pharmaceuticals, Inc. | 50.60M |
| Corcept Therapeutics, Inc. | 241.72M |
| Veru, Inc. | 11.76M |